Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16547228 | 0.89 | MAP3K14 (0.52) | MAP3K14HDAC8AURKBMAPK1FGFR2 | |
| SCHEMBL16547230 | 0.89 | MAP3K14 (0.62) | MAP3K14AURKBMAPK1MET | |
| SCHEMBL16532610 | 0.87 | ELANE (0.40) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16516884 | 0.86 | ELANE (0.46) | MAP3K14HDAC8AURKBMAPK1ELANE | |
| SCHEMBL16532430 | 0.81 | MAP3K14 (0.44) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16532324 | 0.81 | ELANE (0.49) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16534158 | 0.81 | ELANE (0.43) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16532452 | 0.80 | ELANE (0.41) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16547227 | 0.79 | ELANE (0.44) | MAP3K14ELANERPA1METGAA | |
| SCHEMBL16547226 | 0.79 | ELANE (0.41) | MAP3K14ELANERPA1METGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885HDAC8 599/4885AURKB 771/4885 |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885HDAC8 599/4885AURKB 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.